Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta-derived mesenchymal stem cell secretome antimicrobial lock for hemodialysis catheter infection
IRCT20201108049311N8Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Mar 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of vancomycin, ceftazidime and heparin in catheter infection (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Incidence of infection and Incidence of ague. Started Mar 2024; status: completed.
02
Drugs
vancomycinceftazidimeheparin
03
Conditions
catheter infection
Beyond the preview
Go deeper on IRCT20201108049311N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201108049311N8.